Alteration in faecal bile acids, gut microbial composition and diversity after laparoscopic sleeve gastrectomy.
Adult
Bacterial Load
Bile Acids and Salts
/ analysis
Biodiversity
Diabetes Mellitus, Type 2
/ microbiology
Feces
/ chemistry
Female
Gastrectomy
/ methods
Gastrointestinal Microbiome
/ genetics
Humans
Hydrogen-Ion Concentration
Laparoscopy
/ statistics & numerical data
Male
Obesity, Morbid
/ microbiology
RNA, Ribosomal, 16S
/ genetics
Journal
The British journal of surgery
ISSN: 1365-2168
Titre abrégé: Br J Surg
Pays: England
ID NLM: 0372553
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
09
01
2020
revised:
02
03
2020
accepted:
06
04
2020
pubmed:
21
5
2020
medline:
3
3
2021
entrez:
21
5
2020
Statut:
ppublish
Résumé
Laparoscopic sleeve gastrectomy (LSG) is a well established treatment for severe obesity and type 2 diabetes. Although the gut microbiota is linked to the efficacy of LSG, the underlying mechanisms remain elusive. The effect of LSG for morbid obesity on the gut microbiota and bile acids was assessed here. Severely obese subjects who were candidates for LSG were included and followed until 6 months after surgery. The composition and abundance of the microbiota and bile acids in faeces were assessed by 16S ribosomal RNA sequencing, quantitative PCR and liquid chromatography-mass spectrometry. In total, 28 patients with a mean(s.d.) BMI of 44·2(6·6) kg/m LSG is associated with a reduction in faecal bile acids and greater abundance of specific bacterial taxa and α-diversity that may contribute to the metabolic changes. La gastrectomía vertical laparoscópica (laparoscopic sleeve gastrectomy, LSG) es un tratamiento bien establecido para la obesidad grave y la diabetes tipo 2. Aunque la microbiota intestinal se ha vinculado con la eficacia de LSG, los mecanismos subyacentes siguen siendo poco conocidos. En este estudio se evaluó el efecto de LSG en la obesidad mórbida sobre la microbiota del intestino y de los ácidos biliares (bile acids, BA). MÉTODOS: Tras la aprobación del Comité ético y la obtención del consentimiento informado, los sujetos con obesidad grave que eran candidatos para LSG fueron incluidos en el estudio y seguidos durante 6 meses después de la operación. Se evaluaron la composición y abundancia de la microbiota y BA en las heces mediante secuenciación del gen 16S rRNA, PCR cuantitativa y cromatografía líquida-espectrometría de masas. En total, 28 pacientes con una mediana (rango) del IMC de 43,9 kg/m
Sections du résumé
BACKGROUND
Laparoscopic sleeve gastrectomy (LSG) is a well established treatment for severe obesity and type 2 diabetes. Although the gut microbiota is linked to the efficacy of LSG, the underlying mechanisms remain elusive. The effect of LSG for morbid obesity on the gut microbiota and bile acids was assessed here.
METHODS
Severely obese subjects who were candidates for LSG were included and followed until 6 months after surgery. The composition and abundance of the microbiota and bile acids in faeces were assessed by 16S ribosomal RNA sequencing, quantitative PCR and liquid chromatography-mass spectrometry.
RESULTS
In total, 28 patients with a mean(s.d.) BMI of 44·2(6·6) kg/m
CONCLUSION
LSG is associated with a reduction in faecal bile acids and greater abundance of specific bacterial taxa and α-diversity that may contribute to the metabolic changes.
ANTECEDENTES
La gastrectomía vertical laparoscópica (laparoscopic sleeve gastrectomy, LSG) es un tratamiento bien establecido para la obesidad grave y la diabetes tipo 2. Aunque la microbiota intestinal se ha vinculado con la eficacia de LSG, los mecanismos subyacentes siguen siendo poco conocidos. En este estudio se evaluó el efecto de LSG en la obesidad mórbida sobre la microbiota del intestino y de los ácidos biliares (bile acids, BA). MÉTODOS: Tras la aprobación del Comité ético y la obtención del consentimiento informado, los sujetos con obesidad grave que eran candidatos para LSG fueron incluidos en el estudio y seguidos durante 6 meses después de la operación. Se evaluaron la composición y abundancia de la microbiota y BA en las heces mediante secuenciación del gen 16S rRNA, PCR cuantitativa y cromatografía líquida-espectrometría de masas.
RESULTADOS
En total, 28 pacientes con una mediana (rango) del IMC de 43,9 kg/m
Autres résumés
Type: Publisher
(spa)
La gastrectomía vertical laparoscópica (laparoscopic sleeve gastrectomy, LSG) es un tratamiento bien establecido para la obesidad grave y la diabetes tipo 2. Aunque la microbiota intestinal se ha vinculado con la eficacia de LSG, los mecanismos subyacentes siguen siendo poco conocidos. En este estudio se evaluó el efecto de LSG en la obesidad mórbida sobre la microbiota del intestino y de los ácidos biliares (bile acids, BA). MÉTODOS: Tras la aprobación del Comité ético y la obtención del consentimiento informado, los sujetos con obesidad grave que eran candidatos para LSG fueron incluidos en el estudio y seguidos durante 6 meses después de la operación. Se evaluaron la composición y abundancia de la microbiota y BA en las heces mediante secuenciación del gen 16S rRNA, PCR cuantitativa y cromatografía líquida-espectrometría de masas.
Substances chimiques
Bile Acids and Salts
0
RNA, Ribosomal, 16S
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1673-1685Informations de copyright
© 2020 BJS Society Ltd Published by John Wiley & Sons Ltd.
Références
Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014; 384: 766-781.
Lee W-J, Almalki O. Recent advancements in bariatric/metabolic surgery. Ann Gastroenterol Surg 2017; 1: 171-179.
Herrera MF, García-García E, Arellano-Ramos JF, Madero MA, Aldrete-Velasco JA, Corvalá JAL. Metabolic surgery for the treatment of diabetes mellitus positioning of leading medical associations in Mexico. Obes Surg 2018; 28: 3474-3483.
Borisenko O, Lukyanov V, Ahmed AR. Cost-utility analysis of bariatric surgery. Br J Surg 2018; 105: 1328-1337.
Mancini MC. Diretrizes Brasileiras de Obesidade 2016. Associação Brasileira para o Estudo da Obesidade e da Síndrome Metabólica: Sño Paulo, 2016. https://www.researchgate.net/publication/314405519 [accessed 1 April 2018].
Ramos RJ, Mottin CC, Alves LB, Benzano D, Padoin AV. Effect of size of intestinal diversions in obese patients with metabolic syndrome submitted to gastric bypass. Arq Bras Cir Dig 2016; 29(suppl 1): 15-19.
Sasaki A, Wakabayashi G, Yonei Y. Current status of bariatric surgery in Japan and effectiveness in obesity and diabetes. J Gastroenterol 2014; 49: 57-63.
Naitoh T, Kasama K, Seki Y, Ohta M, Oshiro T, Sasaki A et al. Efficacy of sleeve gastrectomy with duodenal-jejunal bypass for the treatment of obese severe diabetes patients in Japan: a retrospective multicenter study. Obes Surg 2018; 28: 497-505.
Samczuk P, Ciborowski M, Kretowski A. Application of metabolomics to study effects of bariatric surgery. J Diabetes Res 2018; 2018: 1-13.
Murad AJ, Cohen RV, de Godoy EP, Scheibe CL, Campelo GP, Ramos AC et al. A prospective single-arm trial of modified long biliopancreatic and short alimentary limbs Roux-en-Y gastric bypass in type 2 diabetes patients with mild obesity. Obes Surg 2017; 28: 599-605.
Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G et al. Richness of human gut microbiome correlates with metabolic markers. Nature 2013; 500: 541-546.
Cani PD. Human gut microbiome: hopes, threats and promises. Gut 2018; 67: 1716-1725.
Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 2005; 102: 11 070-11 075.
Vaughn AC, Cooper EM, DiLorenzo PM, O'Loughlin LJ, Konkel ME, Peters JH et al. Energy-dense diet triggers changes in gut microbiota, reorganization of gut-brain vagal communication and increases body fat accumulation. Acta Neurobiol Exp (Wars) 2017; 77: 18-30.
Sen T, Cawthon CR, Ihde BT, Hajnal A, DiLorenzo PM, de La Serre CB et al. Diet-driven microbiota dysbiosis is associated with vagal remodeling and obesity. Physiol Behav 2017; 173: 305-317.
Haeusler RA, Camastra S, Nannipieri M, Astiarraga B, Castro-Perez J, Xie D et al. Increased bile acid synthesis and impaired bile acid transport in human obesity. J Clin Endocrinol Metab 2016; 101: 1935-1944.
Zheng X, Wang S, Jia W. Calorie restriction and its impact on gut microbial composition and global metabolism. Front Med 2018; 12: 634-644.
Liou AP, Paziuk M, Luevano JM Jr, Machineni S, Turnbaugh PJ, Kaplan LM. Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci Transl Med 2013; 5: 178ra41.
Pedersen HK, Gudmundsdottir V, Nielsen HB, Hyotylainen T, Nielsen T, Jensen BA et al. Human gut microbes impact host serum metabolome and insulin sensitivity. Nature 2016; 535: 376-381.
Liu R, Hong J, Xu X, Feng Q, Zhang D, Gu Y et al. Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention. Nat Med 2017; 23: 859-868.
Fiorucci S, Distrutti E. Bile acid-activated receptors, intestinal microbiota, and the treatment of metabolic disorders. Trends Mol Med 2015; 21: 702-714.
Kohli R, Myronovych A, Tan BK, Salazar-Gonzalez RM, Miles L, Zhang W et al. Bile acid signaling: mechanism for bariatric surgery, cure for NASH? Dig Dis 2015; 33: 440-446.
Ryan KK, Tremaroli V, Clemmensen C, Kovatcheva-Datchary P, Myronovych A, Karns R et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature 2014; 509: 183-188.
Yokota A, Fukiya S, Islam KBM, Ooka T, Ogura Y, Hayashi T et al. Is bile acid a determinant of the gut microbiota on a high-fat diet? Gut Microbes 2012; 3: 455-459.
Li Y, Tang R, Leung PSC, Gershwin ME, Ma X. Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases. Autoimmun Rev 2017; 16: 885-896.
Pucci A, Batterham RL. Mechanisms underlying the weight loss effects of RYGB and SG: similar, yet different. J Endocrinol Invest 2019; 42: 117-128.
Guo Y, Huang ZP, Liu CQ, Qi L, Sheng Y, Zou DJ. Modulation of the gut microbiome: a systematic review of the effect of bariatric surgery. Eur J Endocrinol 2018; 178: 43-56.
Matsuki T, Watanabe K, Fujimoto J, Takada T, Tanaka R. Use of 16S rRNA gene-targeted group-specific primers for real-time PCR analysis of predominant bacteria in human feces. Appl Environ Microbiol 2004; 70: 7220-7228.
Caporaso JG, Lauber CL, Walters WA, Berg-Lyons D, Huntley J, Fierer J et al. Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms. ISME J 2012; 6: 1621-1624.
Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods 2010; 7: 335-336.
Hagio M, Matsumoto M, Fukushima M, Hara H, Ishizuka S. Improved analysis of bile acids in tissues and intestinal contents of rats using LC/ESI-MS. J Lipid Res 2009; 50: 173-180.
Matsumoto K, Takada T, Shimizu K, Moriyama K, Kawakami K, Hirano K et al. Effects of a probiotic fermented milk beverage containing Lactobacillus casei strain Shirota on defecation frequency, intestinal microbiota, and the intestinal environment of healthy individuals with soft stools. J Biosci Bioeng 2010; 110: 547-552.
Shima R, Amamoto R, Kaga C, Kado Y, Sasai T, Watanabe O. Association of life habits and fermented milk intake with stool frequency, defecatory symptoms, and intestinal microbiota in healthy Japanese adults. Benef Microbes 2019; 10: 841-854.
Damms-Machado A, Mitra S, Schollenberger AE, Kramer KM, Meile T, Königsrainer A et al. Effects of surgical and dietary weight loss therapy for obesity on gut microbiota composition and nutrient absorption. Biomed Res Int 2015; 2015: 806248.
Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A 2013; 110: 9066-9071.
Watanabe M, Fukiya S, Yokota A. Comprehensive evaluation of the bactericidal activities of free bile acids in the large intestine of humans and rodents. J Lipid Res 2017; 58: 1143-1152.
Albaugh VL, Banan B, Ajouz H, Abumrad NN, Flynn CR. Bile acids and bariatric surgery. Mol Aspects Med 2017; 56: 75-89.
Goodrich JK, Waters JL, Poole AC, Sutter JL, Koren O, Blekhman R et al. Human genetics shape the gut microbiome. Cell 2014; 159: 789-799.
Oki K, Toyama M, Banno T, Chonan O, Benno Y, Watanabe K. Comprehensive analysis of the fecal microbiota of healthy Japanese adults reveals a new bacterial lineage associated with a phenotype characterized by a high frequency of bowel movements and a lean body type. BMC Microbiol 2016; 16: 284.
Prinz P, Hofmann T, Ahnis A, Elbelt U, Goebel-Stengel M, Klapp BF et al. Plasma bile acids show a positive correlation with body mass index and are negatively associated with cognitive restraint of eating in obese patients. Front Neurosci 2015; 9: 199.
Haeusler RA, Astiarraga B, Camastra S, Accili D, Ferrannini E. Human insulin resistance is associated with increased plasma levels of 12α-hydroxylated bile acids. Diabetes 2013; 62: 4184-4191.
Suganami T, Nishida J, Ogawa Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arterioscler Thromb Vasc Biol 2005; 25: 2062-2068.
ElGeidie A, ElHemaly M, Hamdy E, El Sorogy M, AbdelGawad M, GadElHak N. The effect of residual gastric antrum size on the outcome of laparoscopic sleeve gastrectomy: a prospective randomized trial. Surg Obes Relat Dis 2015; 11: 997-1003.
Alemán JO, Bokulich NA, Swann JR, Walker JM, De Rosa JC, Battaglia T et al. Fecal microbiota and bile acid interactions with systemic and adipose tissue metabolism in diet-induced weight loss of obese postmenopausal women. J Transl Med 2018; 16: 244.
Mima K, Nishihara R, Qian ZR, Cao Y, Sukawa Y, Nowak JA et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut 2016; 65: 1973-1980.
Kostic AD, Chun E, Robertson L, Glickman JN, Gallini CA, Michaud M et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 2013; 14: 207-215.
Takaishi H, Matsuki T, Nakazawa A, Takada T, Kado S, Asahara T et al. Imbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease. Int J Med Microbiol 2008; 298: 463-472.
Ohigashi S, Sudo K, Kobayashi D, Takahashi O, Takahashi T, Asahara T et al. Changes of the intestinal microbiota, short chain fatty acids, and fecal pH in patients with colorectal cancer. Dig Dis Sci 2013; 58: 1717-1726.
Hasegawa S, Goto S, Tsuji H, Okuno T, Asahara T, Nomoto K et al. Intestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in Parkinson's disease. PLoS One 2015; 10: e0142164.